



Ref: Syn/CS/SE/PR/2024-25/Feb/03

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

February 10, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled “**Syngene International announces Leadership changes**”.

The above-mentioned press release will also be available on the website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Head Legal, Company Secretary & Compliance Officer

Enclosed: Press Release

Press Release

Syngene International announces Leadership changes

Bangalore, February 10, 2025: Syngene International Limited today announced that Jonathan Hunt has stepped down from his role as MD&CEO as well as from the Board of Directors to pursue other opportunities in due course. Consequent to this, the Board has appointed Peter Bains as the CEO Designate of Syngene. Both changes are effective immediately, i.e., February 10, 2025.

Commenting on the announcement, **Kiran Mazumdar-Shaw, Non-Executive Chairperson, Syngene International**, said, *“After almost 10 years with Syngene International as MD & CEO, Jonathan Hunt will be leaving to pursue other opportunities. The Board thanks Jonathan for his many contributions to the growth of the Syngene business since April 2016 and its impressive value enhancement over the last decade and wishes him well in his future endeavours.”*

Peter Bains has over three decades of experience in the biotech and pharmaceutical industry. Peter also served as CEO of Syngene from June 2010 to March 2016 and was instrumental in creating a strong foundation for the business and taking it public in 2015. Peter's deep domain experience, knowledge, and familiarity with the business, together with his leadership acumen makes him eminently qualified to step into this role.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.2 Mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com For the Company's latest Environmental, Social, and Governance (ESG) report, visit <https://esgreport.syngeneintl.com>.

Contact Details

Pramuch Goel
Head – Corporate Affairs
E: pramuch.goel@syngeneintl.com